AbbVie's strong financials and potential for cash flow make it a valuable investment, despite risks from patent expirations.

The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...

High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, ...

Evolus faces sector instability but shows strong growth potential. Learn why EOLS stock remains a “Buy” despite challenges, ...

Baby boomers and users of weight loss drugs suffering from “facial sagging” are flocking to injectable aesthetic treatments ...

AbbVie’s ABBV stock has declined 8% in the past three months. A lot of this price decline is due to the poor performance of ...

AbbVie’s CNS portfolio generated more than $5.6 billion in the first nine months of this year and includes clinical applications of botulinum neurotoxin therapy Botox for conditions like ...

We thought Botox might be used to treat other new indications such as ... In 2020, it was acquired by AbbVie, which has been a good parent by investing in research. I still own shares, which has made ...

It's encouraging to see that AbbVie has been growing its earnings per share at 5.7% a year over the past five years. While EPS is growing at a decent rate, but future growth could be limited by ...

Allergan Aesthetics, an AbbVie company, introduced AMI Business Education, a new addition to its AMI Online platform.